{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:13:34Z","timestamp":1790738014091,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10549-025-07839-8","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:32:03Z","timestamp":1763717523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6"],"prefix":"10.1007","volume":"215","author":[{"given":"Leandro Jonata Carvalho","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Senna","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"5","key":"7839_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol 18(5):297\u2013312. https:\/\/doi.org\/10.1038\/s41571-020-00457-x","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"7839_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC (2022) ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol 33(8):750\u2013768. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.520","journal-title":"Ann Oncol"},{"issue":"2","key":"7839_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20(2):71\u201388. https:\/\/doi.org\/10.1038\/s41576-018-0071-5","journal-title":"Nat Rev Genet"},{"issue":"3","key":"7839_CR4","doi-asserted-by":"publisher","first-page":"e481114","DOI":"10.1200\/EDBK-25-481114","volume":"45","author":"JV Aredo","year":"2025","unstructured":"Aredo JV, Jamali A, Zhu J, Heater N, Wakelee HA, Vaklavas C, Anagnostou V, Lu J (2025) Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring. Am Soc Clin Oncol Educ Book 45(3):e481114. https:\/\/doi.org\/10.1200\/EDBK-25-481114","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"7839_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/ctrv.1999.0151","volume":"26","author":"KL Cheung","year":"2000","unstructured":"Cheung KL, Graves CRL, Robertson JFR (2000) Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26(2):91\u2013102. https:\/\/doi.org\/10.1053\/ctrv.1999.0151","journal-title":"Cancer Treat Rev"},{"issue":"9747","key":"7839_CR6","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","volume":"376","author":"GJ Rustin","year":"2010","unstructured":"Rustin GJ, Van Der Burg Me, Griffin CL, Guthrie D, Lamont A, Jayson GC et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial. Lancet 376(9747):1155\u20131163","journal-title":"Lancet"},{"issue":"6","key":"7839_CR7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JOP.2015.005215","volume":"11","author":"C Van Poznak","year":"2015","unstructured":"Van Poznak C, Harris LN, Somerfield MR (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Oncol Pract 11(6):514\u2013516","journal-title":"J Oncol Pract"},{"issue":"8","key":"7839_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781\u2013791","journal-title":"N Engl J Med"},{"issue":"5","key":"7839_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/annonc\/mdm558","volume":"19","author":"F Nol\u00e9","year":"2008","unstructured":"Nol\u00e9 F, Munzone E, Zorzino L, Minchella I, Salvatati M, Botteri E et al (2008) Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 19(5):891\u2013897","journal-title":"Ann Oncol"},{"issue":"4","key":"7839_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","volume":"15","author":"FC Bidard","year":"2014","unstructured":"Bidard FC, Peeters DJ, Fehm T, Nol\u00e9 F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Cara\u00f1ana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15(4):406\u2013414. https:\/\/doi.org\/10.1016\/S1470-2045(14)70069-5","journal-title":"Lancet Oncol"},{"issue":"31","key":"7839_CR11","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","volume":"32","author":"JB Smerage","year":"2014","unstructured":"Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G et al (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32(31):3483\u20133489","journal-title":"J Clin Oncol"},{"issue":"27","key":"7839_CR12","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.22.01063","volume":"40","author":"NL Henry","year":"2022","unstructured":"Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM et al (2022) Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 40(27):3205\u20133221","journal-title":"J Clin Oncol"},{"issue":"10","key":"7839_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","volume":"23","author":"M Will","year":"2023","unstructured":"Will M, Liang J, Metcalfe C, Chandarlapaty S (2023) Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat Rev Cancer 23(10):673\u2013685. https:\/\/doi.org\/10.1038\/s41568-023-00604-3","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"7839_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, De La Motte Rouge T, Sabatier R, Dubot C, Frenel J-S, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier M-A, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D\u2019Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon J-L, Pistilli B, Andr\u00e9 F, Arnould L, Pradines A, Bi\u00e8che I, Callens C, Lemonnier J, Berger F, Delaloge S, Soulie P, Jacquin J-P, Garnier Tixidre C, Delbaldo C, Moreau L, Cheneau C, Paitel J-F, Bernard-Marty C, Spaeth D, Genet D, Moullet I, Bonichon-Lamichhane N, Deiana L, Greilsamer C, Venat-Bouvet L, Delecroix V, Melis A, Orfeuvre H, Nguyen S, Legouffe E, Zannetti A, Le Scodan R, Dohollou N, Dalivoust P, Arsene O, Marques N, Petit T, Mollon D, Dauba J, Bonnin N, Morvan F, Gardner M, Marti A, Levache C-B, Lachaier E, Achille M, Valmar C, Bouaita R, Medioni J, Foa C, Del Piano F, Gozy M, Escande A, Leduc N, Lucas B, Mille D, Ammarguellat H, Najem A, Trouboul F, Barthelemy P, Desclos H, Mayeur D, Lorchel F, Guinet F, Laurenty A-P, Boudrant A, Gisserot O, Alleaume C, De Gramont A (2022) Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 23(11):1367\u20131377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00555-1","journal-title":"Lancet Oncol"},{"key":"7839_CR15","unstructured":"Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, et al 2025 First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer. N Engl J Med. June;NEJMoa2502929."},{"issue":"28","key":"7839_CR16","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F et al (2022) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 40(28):3246\u20133256","journal-title":"J Clin Oncol"},{"issue":"18","key":"7839_CR17","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.23.01500","volume":"42","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q et al (2024) Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. J Clin Oncol 42(18):2149\u20132160","journal-title":"J Clin Oncol"},{"issue":"12","key":"7839_CR18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P et al (2025) Imlunestrant with or without Abemaciclib in advanced breast cancer. N Engl J Med 392(12):1189\u20131202","journal-title":"N Engl J Med"},{"key":"7839_CR19","unstructured":"Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. N Engl J Med. 2025 May 31;NEJMoa2505725."},{"key":"7839_CR20","doi-asserted-by":"publisher","first-page":"104869","DOI":"10.1016\/j.esmoop.2025.104869","volume":"10","author":"CS Manich","year":"2025","unstructured":"Manich CS, Carey LA, Curigliano G, Harbeck N, O\u2019Shaughnessy J, Bidard FC et al (2025) 297O imlunestrant (Imlu) with or without abemaciclib (Abema) in advanced breast cancer (ABC): a subgroup analysis in CDK4\/6 inhibitor (CDK4\/6i)-pretreated patients (pts) from EMBER-3. ESMO Open 10:104869","journal-title":"ESMO Open"},{"issue":"12","key":"7839_CR21","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.23.01521","volume":"42","author":"J Remon","year":"2024","unstructured":"Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R et al (2024) Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR -mutant non\u2013small-cell lung cancer. J Clin Oncol 42(12):1350\u20131356","journal-title":"J Clin Oncol"},{"issue":"3","key":"7839_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","volume":"7","author":"W Toy","year":"2017","unstructured":"Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM et al (2017) Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov 7(3):277\u2013287","journal-title":"Cancer Discov"},{"issue":"2","key":"7839_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","volume":"14","author":"B Kingston","year":"2024","unstructured":"Kingston B, Pearson A, Herrera-Abreu MT, Sim LX, Cutts RJ, Shah H et al (2024) ESR1 F404 mutations and acquired resistance to Fulvestrant in ESR1 -mutant breast cancer. Cancer Discov 14(2):274\u2013289","journal-title":"Cancer Discov"},{"issue":"12","key":"7839_CR24","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45(12):1439\u20131445. https:\/\/doi.org\/10.1038\/ng.2822","journal-title":"Nat Genet"},{"issue":"1","key":"7839_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41523-019-0121-y","volume":"5","author":"A Marra","year":"2019","unstructured":"Marra A, Curigliano G (2019) Are all cyclin-dependent kinases 4\/6 inhibitors created equal? Npj Breast Cancer 5(1):27","journal-title":"Npj Breast Cancer"},{"issue":"1","key":"7839_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A et al (2025) Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. Npj Precis Oncol 9(1):84","journal-title":"Npj Precis Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07839-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:39:01Z","timestamp":1767789541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07839-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7839"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07839-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. CHB:  Grants\/research support: (to the institution) Amgen, Astra Zeneca, Aveo Oncology, BioNTech, BMS, Daiichi Sankyo, Dizal Pharma, Exelixis, Fortrea, Gilead Sciences, GSK, ICON, IQVIA, Janssen, Labcorp, Lilly, Medpace, MSD, Novartis, Novocure, Nuvisan, OBI Pharma, Parexel, Pfizer, PharmaMar, PPD, PSI, Regeneron, Roche\/Genentech, Samsung, Sandoz,  Sanofi, Seagen, Servier, Stemline, Syneos Health, Taiho, Takeda, Tolmar, TRIO, Worldwide. Ownership or Stocks: Tummi, MEDSir, CPO. Advisory Boards, Consulting, Travel, Presentation Honoraria: Adium, Novartis, Pfizer, Roche\/Genentech, MSD, Astra Zeneca, Lilly, Daiichi, Gilead. RD: Speaker fee from Roche, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp & Dohme, Lilly, AstraZeneca, Janssen, Takeda, Bristol Myers Squibb, GlaxoSmithKline, Gilead, Novartis, Daiichi-Sankyo and GlaxoSmithKline. Consultation or advisory fees from Roche, Foundation Medicine, AstraZeneca.  Support for attending meeting from AstraZeneca, Daiichi-Zankyo. Grants from Merck, Novartis, Daiichi-Sankyo, GlaxoSmithKline and AstraZeneca. Equity and stock owner of the Trialing Health. All the other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"5"}}